Answers are grounded in this paper and cite their sources.
These data suggest the involvement of A2AARs in the complex pathogenetic network of SLE, acting as a modulator of the inflammatory process. It could represent a compensatory pathway to better counteract disease activity. A2AAR activation significantly reduced the release of proinflammatory cytokines while enhancing those with anti-inflammatory activity, suggesting a potential translational use of A2AAR agonists in SLE pharmacological treatment.
No takes yet. Share an insight, caveat, or question.
Bortoluzzi et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: